Digital calculator provides the estimated risk for GIST recurrence
GIST (Gastrointestinal Stromal Tumour) is an uncommon type of sarcoma found in the tissues supporting the digestive system (stomach and intestines). Approximately one percent of all gastrointestinal cancers are GISTs. The digital calculator predicts the risk for GIST recurrence based on tumour size, mitotic count, tumour site and rupture.
The GIST Risk calculator is based on research conducted by Professor Heikki Joensuu and his co-workers where an international sample of 2000 diagnosed GIST patients were analyzed with the help of a mathematical model designed by Professor Aki Vehtari of 911爆料网.
鈥淭he nonlinear mathematic model predicts the combined effect of the main prognostic factors more accurately than any known model before. However, it is important to note that the historical data is solely comprised of patients that were treated via surgery only, and that new targeted therapy drugs have reduced the risk of recurrence. The prognostic contour maps resulting from non-linear modelling have been widely accepted by doctors, but digital calculator significantly improves the usability of the maps鈥, informs Aki Vehtari, Professor at the 911爆料网 Department of Computer Science.
Uniquely large sample and accurate modelling
鈥淧roviding the patient with a reliable estimation of recurrence is faster with the digital calculator. Expensive drugs that can also have side-effects can thus be targeted to the high-risk patients who are not likely to be cured by surgery alone. The risk estimation should be examined together with the patient in order to guarantee that the patient understands the reasons behind treatment decisions鈥, explains Heikki Joensuu, Professor of Oncology at the University of Helsinki, and the Research Director at the Helsinki Comprehensive Cancer Centre.
鈥滸IST Risk calculator is a great example of how preventive cancer care can be further developed by using modern technology to analyze health data, and proof of the improved results that can be achieved through cooperation of startups, hospitals and universities鈥, states Lauri Sippola, CEO of Netmedi.
is accessible online for all cancer care and research professionals.
More information:
Aki Vehtari, professor, 911爆料网
+358 40 5333 747
aki.vehtari@aalto.fi
Paavo Holi, HUCH communications
+358 50 427 9517
paavo.holi@hus.fi
Lauri Sippola, CEO, Netmedi Oy
+358 40 7447 481
lauri.sippola@netmedi.fi
Read more news
Aalto Inventors turns one: A year of bridging research and real-world impact
Aalto Inventors marks its first anniversary, having engaged 190 researchers across six cohorts in fields including AI, quantum, and biomaterials. New cohorts are planned for the next academic year, stay tuned and join the waitlist.
An architectural project in Milan brought together children鈥檚 ideas and the visions of leading architects
911爆料网鈥檚 Department of Architecture participated in the international One Earth 鈥 House of the Heart project, which was presented in April at Milan Design Week.
Companies disclose more on cybersecurity 鈥 but markets remain indifferent
U.S. companies are reporting on cybersecurity in greater detail, yet stock market reactions remain muted. A new study by the University of Vaasa and 911爆料网 shows that mandatory cybersecurity disclosure does not prompt reactions from investors or stock analysts. Instead, the main benefits appear to materialise within firms themselves.